Phase 2 Hyper-CVAD/Rituximab for Untreated Mantle Cell Lymphoma: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Phase 2 Hyper-CVAD/Rituximab for Untreated Mantle Cell Lymphoma (NCT00581854), a na phase 2 study. The primary outcome is Complete Response Rate to Induction Therapy.

2. Clinical Question

3. Trial Design

This was a Phase 2 pilot study in mantle cell lymphoma. The registry describes a single-group model and lists allocation as NA, so participants were not assigned between randomized study arms in the record. Masking is listed as none. The registry reports 22 enrolled participants and a completed status.

The study is titled as an evaluation of Hyper-CVAD plus rituximab for previously untreated mantle cell lymphoma. The regimen description says rituximab and modified Hyper-CVAD were administered every 28 days for 4-6 cycles, followed by rituximab maintenance therapy. Maintenance is described as four weekly doses every six months for two years. The intervention listing names modified Hyper-CVAD; the regimen details come from the study summary.

The registry lists the study start as 2000-06 and primary completion as 2006-06. Its primary outcome is the percentage of participants achieving Complete Response or Complete Response Unconfirmed after induction therapy. The outcome description names the Cheson et al criteria for standardized response criteria (1999), and the timeframe is given as median follow up of 37 months.

A single-group design can describe outcomes among enrolled participants receiving the study regimen, but it does not provide a concurrent control for separating treatment effects from other explanations. The registry record does not report a comparison with usual care or another regimen, a randomization procedure, or a masking procedure beyond listing masking as none. Protocol details beyond the registered information are not reported in the registry record.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Analysis population for the primary outcome, as defined in the registry: All Subjects enrolled were included in the analysis. Response rate is represented as % of total subjects enrolled.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Complete Response Rate to Induction Therapy, measured over Median follow up of 37 months.

The primary endpoint is the percentage of enrolled participants who achieved either a Complete Response (CR) or Complete Response Unconfirmed (CRu) after induction therapy. The registry says the response classification followed the Cheson et al criteria for standardized response criteria (1999). It also specifies that all subjects enrolled were included in the analysis and that the response rate is represented as a percentage of total subjects enrolled.

Response endpoints are used to describe whether participants meet prespecified criteria for a change in disease status. Combining CR and CRu into the endpoint means the registered measure counts either category as a response; it does not report them separately. The endpoint is a binary outcome at the participant level: each participant is classified according to whether the response definition is met, and the group result is expressed as a percentage.

The registry lists a 90% Confidence Interval as the dispersion measure and gives median follow up of 37 months as the timeframe. The response percentage and interval are not reported in the registry record. The record also does not explain how the stated follow-up timeframe relates to the timing of the post-induction response assessment.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

For the primary endpoint, each participant is classified according to whether they achieved CR or CRu after induction therapy. The group response rate is expressed as a percentage of enrolled subjects. In general, a binary endpoint records whether a specified event or condition occurred for each participant; it is different from a continuous measure such as a laboratory value. The registry describes the response criteria and analysis population, but does not report the resulting percentage.

What does a confidence interval communicate?

In general, a confidence interval expresses statistical uncertainty around an estimate. Its width gives information about precision: a wider interval represents less precision than a narrower interval under the method’s assumptions. The registry identifies a 90% Confidence Interval as the dispersion measure for the primary endpoint, but the interval limits are not reported in the registry record. Without the estimate and limits, the precision of the response rate cannot be judged from the record.

A confidence interval is not a guarantee that the true value falls within a particular interval, nor does it address every source of uncertainty. It reflects sampling uncertainty under the statistical procedure used. It does not correct for limitations in study design, missing outcome information, or differences between the enrolled participants and other populations. The specific interval construction method is not reported in the registry record.

Why does the study structure matter?

In general, a single-group study estimates outcomes within the group that received the intervention. It does not create a direct treatment contrast with a concurrent control group. A randomized comparison can help balance participant characteristics across groups, on average, while a single-group study cannot use that design feature to distinguish treatment effects from other potential explanations. This study is listed as single group, with allocation NA and masking none. A randomized allocation method and a control arm are not reported in the registry record.

The primary endpoint is a proportion, and in general the precision of a proportion depends partly on the number of participants and the distribution of outcomes. The registry lists 22 enrolled participants, but does not report a numerical response estimate or confidence interval. No further precision assessment should be inferred from the enrollment figure alone.

What can planning calculations tell readers?

In general, sample-size planning asks how many participants a future study might need to detect a specified effect under chosen assumptions. The registry’s planning description states that its illustration uses a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation, with the effect to detect set as a stated fraction of the observed effect. Those are planning assumptions, not a description of this single-group trial’s allocation. The registry also distinguishes participant-per-arm calculations from total-event calculations for time-to-event outcomes.

Any such planning illustration is hypothetical and depends on its assumptions. It is not an observed property of the completed study and is not evidence that the study had a particular probability of detecting an effect. No numerical planning estimate or stated effect fraction is reported in the registry record. The trial’s own sample-size justification and design assumptions are not reported in the registry record.

How should event counts be read?

In general, adverse-event counts describe how many participants were recorded as affected within a defined group, while percentages express a frequency relative to a denominator. Seriousness and event type are separate classifications. A listed term may not represent a unique person, and several terms may occur in the same participant; interpretation requires definitions and event-level information. The registry provides group counts and selected serious-event terms, but does not report the detailed rules needed to determine overlap, timing, duration, or severity assessment beyond the terms shown.

Over-dispersion is a general concern when counts vary more than a chosen statistical model expects. In a binary endpoint analysis, standard assumptions may not describe all sources of variation, such as clustering or differences among participants. The registry does not report a model for the primary outcome or information about clustering, so no over-dispersion assessment can be attributed to this study.

10. Exact Estimates for Each Arm

No two-arm comparison is shown for this trial, but each arm's result can still be summarized with exact interval estimates computed from the posted counts. The Clopper-Pearson interval is exact and conservative; the Wilson interval is a common closer-to-nominal alternative; the Bayesian credible interval uses a uniform Beta(1, 1) prior. For small groups the three can differ noticeably.

R code and output

arm    <- c("Group 1")
n      <- c(22)
events <- c(14)
for (i in seq_along(n)) {
  ci <- binom.test(events[i], n[i])$conf.int          # Clopper-Pearson exact interval
  cr <- qbeta(c(0.025, 0.975), 1 + events[i], 1 + n[i] - events[i])   # Bayesian, uniform Beta(1,1) prior
  wi <- (function(x, n) { p <- x / n; z <- qnorm(0.975); d <- 1 + z^2 / n
    c((p + z^2 / (2 * n) - z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d, (p + z^2 / (2 * n) + z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d) })(events[i], n[i])
  cat(sprintf("ARM|%s|%d|%d|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f\n", arm[i], n[i], events[i], 100 * events[i] / n[i],
              100 * ci[1], 100 * ci[2], 100 * wi[1], 100 * wi[2], 100 * cr[1], 100 * cr[2]))
}

ARM  Group 1  22  14  63.6  40.7  82.8  43.0  80.3  42.7  80.3

11. Multiplicity, Missing Data and Analysis Populations

The registry lists one outcome measure, the Complete Response Rate to Induction Therapy, and lists 0 analyses. The record therefore does not describe a set of multiple primary endpoints or provide an analysis plan showing how multiple statistical tests were handled. A multiplicity adjustment, testing hierarchy, or prespecified approach to secondary outcomes is not reported in the registry record.

In general, multiplicity arises when several hypotheses are tested or several outcomes are examined. Repeated testing can increase the chance of a false-positive finding if results are interpreted without accounting for the testing strategy. Whether that issue arose in this study cannot be determined from the registry record: it does not give a full analysis plan or report analyses of additional outcomes.

The primary population is stated to include all subjects enrolled, and the response rate is described as a percentage of total subjects enrolled. That specifies the denominator intended by the registry description. It does not explain how the analysis handled participants whose response status could not be assessed, missing records, withdrawal, or incomplete follow-up. Imputation procedures, exclusions, and sensitivity analyses are not reported in the registry record.

In general, missing outcome information can affect a proportion if the chance of missingness is related to response status. The record does not report whether any primary endpoint data were missing or how missingness was assessed. The number with an evaluable response and the number with missing response information are not reported in the registry record. Consequently, the all-enrolled analysis description should not be taken as evidence that every participant had a documented response assessment.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 2% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: neutropenic fever gr 3 (18.2%), infection with febrile neutropenia, gr 3 (9.1%), atrial fibrillation gr 3, dyspnea (4.5%), perionitis, gr 5 (4.5%), psuedomonas sepsis, gr 5 (4.5%).

The serious-event group lists 22 participants at risk and 8 affected. The other-event category lists 22 at risk and 22 affected. These are registry counts for their respective categories; the record does not provide event-level details that would establish whether events overlapped among participants or when they occurred.

The listed serious-event terms are Neutropenic Fever Gr 3 at 18.2%, Infection with febrile neutropenia, Gr 3 at 9.1%, Atrial fibrillation gr 3, dyspnea at 4.5%, perionitis, gr 5 at 4.5%, psuedomonas sepsis, gr 5 at 4.5%, and Hyponatremia, gr 3 at 4.5%. The spellings and grades follow the registry entries. These percentages are attached to individual listed terms and should not be combined into an overall rate; the record does not say whether terms could occur in the same participant.

The deaths field is null, so deaths are not reported in the registry record. Definitions of the adverse-event categories, observation periods, and details on event duration or resolution are not reported. The entries therefore describe the recorded safety summaries, not a complete account of every event or its clinical course.

13. What the Result Does, and Does Not, Mean

The study’s primary question is whether participants receiving the described regimen achieved CR or CRu after induction, expressed as a percentage of enrolled subjects. The registry supplies the endpoint definition, response criteria, analysis population, and a stated 90% Confidence Interval measure. It does not report the response percentage or confidence interval limits. As a result, the primary result’s size and precision cannot be evaluated from the registry record.

The design also limits what an outcome could mean. This is a single-group Phase 2 study rather than a randomized comparison. A response proportion in this group would be a descriptive result for the enrolled participants; it would not establish the comparative effect of the regimen against another treatment. The registry record does not report a concurrent control group or a causal comparison.

The safety entries indicate that 8 participants were recorded as affected in the serious-event category, and 22 were recorded as affected in the other-event category. Selected serious-event terms and their listed percentages provide additional descriptions. They do not, without further detail, establish the overall frequency of every possible event, the degree of overlap among terms, or the timing and duration of events.

These limitations do not erase the study’s descriptive contribution: the record identifies the population, intervention schedule, primary response definition, and selected safety summaries. They do mean that conclusions must stay within those reported details. No claim about treatment benefit, lack of benefit, comparative safety, or generalizability can be established from the registry information alone. The study’s protocol details, primary numerical response result, and analysis methods beyond those described are not reported in the registry record.

14. Why This Trial Matters Statistically

This trial is statistically informative as an example of how a Phase 2, single-group study frames an early clinical question. It defines a binary response endpoint, identifies the response criteria, states the intended analysis population, and specifies a 90% Confidence Interval as the measure of dispersion. These features allow readers to understand what the endpoint was intended to represent, even though the numerical response result is not reported in the registry record.

The case also illustrates why a clearly defined endpoint and a reported estimate are both needed for interpretation. Knowing that CR or CRu counted as response explains the outcome’s meaning, but without the response percentage and its interval, readers cannot assess observed response frequency or statistical precision. An endpoint definition is not a substitute for the result.

The single-group structure demonstrates a separate distinction: estimation within a treated group is not the same as a randomized treatment comparison. Even if an outcome estimate were available, the study design would not by itself establish how outcomes would compare under another regimen. This is a central issue when interpreting early-phase studies and when considering what evidence a subsequent comparative study might need to provide.

Finally, the registry separates the primary endpoint description from safety summaries. Counts and listed event terms can describe what was recorded, but incomplete detail about overlap, timing, missingness, and analysis methods limits further statistical interpretation. The record thus highlights both the value of transparent outcome definitions and the importance of complete outcome reporting.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The most direct limitation for interpreting the primary endpoint is that its numerical result is not reported in the registry record. Although the outcome definition, intended denominator, and 90% Confidence Interval measure are stated, the response percentage and interval limits are absent. Statistical precision and the observed response frequency therefore cannot be assessed.

The single-group design has no concurrent control for comparison. It can describe outcomes in the enrolled population but does not support a randomized estimate of differences between treatments. The registry lists no masking and does not report a randomized allocation procedure.

The registry states that all enrolled subjects were included in the primary analysis, but does not report evaluable response counts, missing response data, or how missing outcomes were handled. It also gives median follow up of 37 months without explaining how that timeframe relates to the induction response assessment. The analysis method and confidence-interval construction are not reported in the registry record.

The safety summaries lack detail on event definitions, timing, duration, recurrence, and possible overlap among the listed terms. The deaths field is null, and deaths are not reported in the registry record. Further eligibility criteria, protocol details, and the study’s sample-size justification are also not reported. These gaps restrict interpretation beyond the descriptive information recorded.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: Phase 2 Hyper-CVAD/Rituximab for Untreated Mantle Cell Lymphoma — NCT00581854.
• Registry record last updated 2019-12-13; status last verified 2019-06.
• Results first posted 2014-07-21.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

NCT00581854 is a completed Phase 2 pilot study of Hyper-CVAD plus rituximab for previously untreated mantle cell lymphoma. The registry lists a single-group model, allocation NA, masking none, and 22 enrolled participants. The regimen description includes modified Hyper-CVAD and rituximab induction every 28 days for 4-6 cycles, followed by rituximab maintenance.

The primary outcome is the percentage achieving CR or CRu after induction, using the Cheson et al criteria for standardized response criteria (1999). All enrolled subjects were intended for inclusion, and a 90% Confidence Interval is specified. The primary numerical result and interval are not reported in the registry record. The record also lists serious and other adverse-event counts and selected serious-event terms, but does not provide detailed event-level information.